LabTube meets Steve Jackson

2019Kate DryApril 25, 2019

On receiving the 47th ARC Foundation Léopold Griffuel Award

2019Kate DryApril 18, 2019

Steve awarded the Fondation ARC Léopold Griffuel Award in Translational and Clinical Research

2019Kate DryFebruary 19, 2019

Novel mechanisms of drug resistance in ATM-deficient cells suggest potential new therapies for cancer and ataxia-telangiectasia

2019Kate DryJanuary 8, 2019

Steve discusses how blue skies research will influence future cancer therapies

2019Kate DryJanuary 8, 2019

Watch That's Cambridge interview with Wellcome Fellow Harveer Dev

2018Kate DryAugust 13, 2018

We, with a group of international collaborators, have identified a novel protein complex (Shieldin) that promotes DNA repair in cells lacking the HR protein BRCA1.

Loss of Shieldin restores genome stability in BRCA1 deficiency

2018Kate DryJuly 19, 2018

Our new paper on "Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells.." is a Focus feature in Science Signaling

2018Kate DryJuly 4, 2018

2018 Hooke Medal awarded to Jackson lab alumnus Andrew McAinsh

2018Kate DryApril 6, 2018

Sébastien Britton, Jackson lab postdoc Jan 2010-April 2013, awarded 2018 CNRS Bronze medal

2018Kate DryApril 5, 2018

Former post-doc Soo-Hwang Teo awarded honorary OBE

2018Kate DryFebruary 13, 2018

Cancer patient Sandy meets Steve Jackson and explains how the ground-breaking drug Lynparza saved her life.

2018Kate DryJanuary 16, 2018

FDA approves first treatment for breast cancer with a certain inherited genetic mutation

2018Kate DryJanuary 12, 2018

Steve gives CMM Anthony Epstein lecture

2017Kate DryDecember 15, 2017

New Review describes the importance of deubiquitylases (DUBs) as key drug targets

2017Kate DryOctober 3, 2017

Celebrating 25 years of the Jackson Lab

2017Kate DryApril 20, 2017

AZ moves closer to Lynparza filing in breast cancer

AZ have announced that they are closer to Lynparza (olaparib) being licensed for the treatment of breast cancer. Lynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy. This is the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.

News

©2016 - Steve Jackson LabOratory